Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Antonysamy

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Sub-Cellular Biochemistry|March 9, 2017
The Structure and Function of the PRMT5:MEP50 ComplexStephen Antonysamy
Bioorganic & Medicinal Chemistry Letters|November 21, 2008
Fragment-based discovery of JAK-2 inhibitorsStephen Antonysamy, Gavin Hirst, Frances Park, et al.
Mabs|July 4, 2024
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapyAmelia C McCue, Stephen J Demarest, Karen J Froning, et al.
Plos One|September 11, 2020
Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packingRicky Lieu, Stephen Antonysamy, Zhanna Druzina, et al.
Plos One|December 25, 2013
Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domainStephen Antonysamy, Bradley Condon, Zhanna Druzina, et al.
Journal of Medicinal Chemistry|May 12, 2015
Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory TherapeuticsJohn Gately Luz, Stephen Antonysamy, Steven L Kuklish, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Crystal structure of the human PRMT5:MEP50 complexStephen Antonysamy, Zahid Bonday, Robert M Campbell, et al.
Plos One|January 13, 2018
Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discoveryJoey P Ting, Frances Tung, Stephen Antonysamy, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor ActivityZahid Q Bonday, Guillermo S Cortez, Michael J Grogan, et al.
Biochimica Et Biophysica Acta. General Subjects|November 27, 2020
Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP)Joseph D Ho, Matthew R Lee, Charles T Rauch, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Sub-Cellular Biochemistry|March 9, 2017
The Structure and Function of the PRMT5:MEP50 ComplexStephen Antonysamy
Bioorganic & Medicinal Chemistry Letters|November 21, 2008
Fragment-based discovery of JAK-2 inhibitorsStephen Antonysamy, Gavin Hirst, Frances Park, et al.
Mabs|July 4, 2024
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapyAmelia C McCue, Stephen J Demarest, Karen J Froning, et al.
Plos One|September 11, 2020
Rapid and robust antibody Fab fragment crystallization utilizing edge-to-edge beta-sheet packingRicky Lieu, Stephen Antonysamy, Zhanna Druzina, et al.
Plos One|December 25, 2013
Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domainStephen Antonysamy, Bradley Condon, Zhanna Druzina, et al.
Journal of Medicinal Chemistry|May 12, 2015
Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory TherapeuticsJohn Gately Luz, Stephen Antonysamy, Steven L Kuklish, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Crystal structure of the human PRMT5:MEP50 complexStephen Antonysamy, Zahid Bonday, Robert M Campbell, et al.
Plos One|January 13, 2018
Utilization of peptide phage display to investigate hotspots on IL-17A and what it means for drug discoveryJoey P Ting, Frances Tung, Stephen Antonysamy, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor ActivityZahid Q Bonday, Guillermo S Cortez, Michael J Grogan, et al.
Biochimica Et Biophysica Acta. General Subjects|November 27, 2020
Structure-based, multi-targeted drug discovery approach to eicosanoid inhibition: Dual inhibitors of mPGES-1 and 5-lipoxygenase activating protein (FLAP)Joseph D Ho, Matthew R Lee, Charles T Rauch, et al.
Pageof 2